The FDA on October 24, 2025, approved REVUFORJ®, a menin inhibitor, for relapsed or refractory Acute Myeloid Leukemia with a susceptible Nucleophosmin 1 (NPM1) mutation in adult and pediatric patients 1 year and older who have no satisfactory alternative treatment options. REVUFORJ® is a product of Syndax Pharmaceuticals, Inc.
Bottom Ad
Advertisement
Subscribe
